JPRN-UMIN000016582CompletedPhase 1
Phase I clinical safety study of Enzyme-treated Asparagus Extract (ETAS) by the healthy subjects (a randomized placebo-controlled trial) - The phase I safety study of Enzyme-treated Asparagus Extract (ETAS)
Osaka University Graduate School of Medicine, Department of Integrative Medicine0 sites50 target enrollmentStarted: April 1, 2015Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 50
Study Overview
Brief Summary
Severe side effects associated with taking formulation were not observed.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) Severe clinical history 2) Pregnancy or the subjects to desire it. 3) Lactation period 4) The subject who cannot measure the body composition by bioelectrical impedance analysis because of equipment of medical machine such as pacemaker or severe dry skin. 5) The case that the doctor judged to be unsuitable for the participation of this examination
Investigators
Similar Trials
Recruiting
Phase 1
Study BT5528-100 in Patients with Advanced Solid Tumors Associated with EphA2 ExpressioAdvanced Malignancies Associated with EphA2 ExpressionMedDRA version: 21.1Level: LLTClassification code: 10065147Term: Malignant solid tumor Class: 10029104CTIS2024-510655-36-00Bicycletx Limited288
Active, not recruiting
Phase 1
A Phase 1-2 Study of the Safety and Activity of ASTX029 in Patients with Advanced Solid TumorsAdvanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864EUCTR2018-004568-72-ESAstex Pharmaceuticals, Inc.300
Active, not recruiting
Phase 1
A Phase 1-2 Study of the Safety and Activity of ASTX029 in Patients with Advanced Solid TumorsAdvanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864EUCTR2018-004568-72-FRAstex Pharmaceuticals, Inc.300
Not yet recruiting
Phase 1
The study to determine whether the child friendly formulations for drug resistant tuberculosis are safe, tolerable and acceptable among children below 15 years of age.CTRI/2020/09/027512Stellenbosch University
Active, not recruiting
Phase 1
Study of the Safety and Pharmacokinetics of Venetoclax in Children and Young Adults with Relapsed or Refractory MalignanciesEUCTR2017-000439-14-FRAbbVie Deutschland GmbH & Co. KG135